Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report

Clovis Oncology Inc. CLVS, -1.18% stock tumbled more than 14% in after-hours trading Friday after the company said it plans to discontinue the phase-two trial evaluating its rucaparib treatment in bladder cancer, according to a report. Clovis halted the trial due to the recommendation of an independent monitoring committee, according to Dow Jones. Clovis said the committee recommendation wasn’t a result of the “safety profile” of the treatment, according to Dow Jones.

Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.

Read More Here...

Bookmark the permalink.